CHESHIRE, Conn., Nov. 9 Alexion Pharmaceuticals,Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnalhemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment forpatients with PNH, have been published by the American Society of Hematology(ASH). Abstracts will be presented at the 2007 ASH annual meeting that isbeing held December 8 to 11, 2007 at the Georgia World Congress Center inAtlanta.
The following abstracts will be presented in a poster session on red cellregulation and disorders of production on Monday, December 10, 2007. Theabstracts and presentation information can be accessed at the links providedbelow.
The following abstract will be presented in an oral session on red cellregulation and disorders of production on Tuesday, December 11, 2007. Theabstract and presentation information can be accessed at the link providedbelow.-- "High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter Hillmen et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416 -- "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204 -- "Disease.Related Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle Meyers et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.
SOURCE Alexion Pharmaceuticals, Inc.